HeartStitch(TM), Inc. Board Strengthened by NURIS' Dr. Kanat Baigarin

LOS ANGELES, CA--(Marketwired - Dec 21, 2015) - HeartStitch^® announced today the election of Dr. Kanat Baigarin, Chief Operating Officer of NURIS in Astana, Kazakhstan, who has joined its Board of Directors. The election took place at a meeting of the Company's stockholders held in November, 2015. Prior to his election, Dr. Baigarin was appointed to the Board in August of 2015 to fill an existing vacancy. Dr. Baigarin joins the board lending his years of knowledge and expertise in Research and Technology to HeartStitch^®. 

Dr. Baigarin is a fellow of the Moscow Institute of Physics and Technology. From 2009 till 2011 he was the Managing Director of Nazarbayev University, and since 2011 he has become a General Director of "Nazarbayev University Research and Innovation System" PI. In 2014 he was further appointed Vice President for Innovation of Nazarbayev University. Dr. Baigarin has been a Member of the Technology Executive Committee (UNFCCC) and National Focal Point for Climate change under the UNFCCC since 1999. He is 57 years of age.

HeartStitch^® held a stockholders meeting in November to elect the members of its Board of Directors. The stockholders elected Prof. Anthony Nobles, Benjamin Brosch, Dr. Kanat Baigarin, and Richard Babcock to serve on the Board.

Dr. Baigarin commented, "I am very excited about the opportunity that HeartStitch^® brings to the world. We are extremely happy to have such technologies being developed here in Kazakhstan. Treatment of cardiac medical conditions is a growing market and a priority for us at NURIS -- and for the many patients in Kazakhstan and around the world that will benefit from these technologies."

Rich Babcock, Esq., Chief Counsel and member of the Board of Directors of HeartStitch^® commented, "Dr. Baigarin brings strong, independent representation to our board. He has years of experience and knowledge that have already been proven by his significant input to the recent HeartStitch^® expansion into Kazakhstan and the CIS region."

Professor Anthony Nobles, CEO and Chairman of the Board of HeartStitch^® commented, "Dr. Baigarin and I both come from technology and management, which allows us to communicate at the same level when discussing HeartStitch^® business and technology. He also has significant skills in dealing with our partners in Kazakhstan and the nearby CIS countries. Dr. Baigarin will continue to be a valuable part of our Board of Directors."

About HeartStitch^®
HeartStitch^® Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the structural heart marketplace. HeartStitch^® is focused on the innovative suture-based systems for remotely providing suture repair of structural heart defects and other vascular structures.

The HeartStitch^® TA and HeartStitch^® MR are FDA cleared for vascular suturing in the United States. The NobleStitch™ EL is FDA cleared for vascular suturing in the United States and CE Marked for cardio-vascular suturing and PFO closure in the European Union.